Inventor · disambiguated record
Asya Grinberg
Also filed as: GRINBERG ASYA
65 granted patents·66 pending applications·202 citations·filing 2007–2025
98Inventor score
Files withACCELERON PHARMA INC74DRAGONFLY THERAPEUTICS INC43GRINBERG ASYA6BRIGHAM & WOMENS HOSPITAL INC3ACCELERON PHARM INC1
Top patents by PatentIndex Score
131 records- 0197US11939384B1Antibody variable domains targeting the NKG2D receptorDRAGONFLY THERAPEUTICS INC·Filed 2023·Granted Mar 26, 2024·9 cites·16 claims
- 0296US11884733B2Antibody variable domains targeting the NKG2D receptorDRAGONFLY THERAPEUTICS INC·Filed 2019·Granted Jan 30, 2024·10 cites·14 claims
- 0396US11834506B2Multi-specific binding proteins that bind NKG2D, CD16, and a tumor-associated antigen for activation of natural killer cells and therapeutic uses thereof to treat cancerDRAGONFLY THERAPEUTICS INC·Filed 2018·Granted Dec 5, 2023·16 cites·18 claims
- 0496US11787864B2Heterodimeric Fc-fused proteinsDRAGONFLY THERAPEUTICS INC·Filed 2022·Granted Oct 17, 2023·13 cites·13 claims
- 0596US9809637B2Transforming growth factor beta receptor II fusion polypeptidesACCELERON PHARMA INC·Filed 2016·Granted Nov 7, 2017·19 cites·9 claims
- 0694US12129300B2Antibody variable domains targeting the NKG2D receptorDRAGONFLY THERAPEUTICS INC·Filed 2023·Granted Oct 29, 2024·1 cites·8 claims
- 0793US11028145B2ALK7:actriib heteromultimers and uses thereofACCELERON PHARMA INC·Filed 2019·Granted Jun 8, 2021·4 cites·23 claims
- 0893US10358476B2Single arm type I and type II receptor fusion proteins and uses thereofACCELERON PHARMA INC·Filed 2016·Granted Jul 23, 2019·12 cites·16 claims
- 0993US10227393B2TGF-beta superfamily type I and type II receptor heteromultimers and uses thereofACCELERON PHARMA INC·Filed 2016·Granted Mar 12, 2019·9 cites·27 claims
- 1091US11279746B2ALK4:ActRIIB heteromultimers and uses thereofACCELERON PHARMA INC·Filed 2020·Granted Mar 22, 2022·2 cites·11 claims
- 1191US10738098B2ALK4:ActRIIB heteromultimers and uses thereofACCELERON PHARMA INC·Filed 2018·Granted Aug 11, 2020·6 cites·33 claims
- 1290US10501547B2ALK7 binding proteins and uses thereofACCELERON PHARMA INC·Filed 2017·Granted Dec 10, 2019·3 cites·7 claims
- 1390US2025066488A1Actriib binding agents and uses thereofACCELERON PHARMA INC·Filed 2024·Application pending·0 cites
- 1489US10906958B2TGF-beta superfamily type I and type II receptor heteromultimers and uses thereofACCELERON PHARMA INC·Filed 2019·Granted Feb 2, 2021·2 cites·4 claims
- 1589US8642031B2Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereofSEEHRA JASBIR·Filed 2009·Granted Feb 4, 2014·4 cites·13 claims
- 1689US8158584B2Pharmaceutical preparations comprising an ALK1-Fc fusion proteinGRINBERG ASYA·Filed 2009·Granted Apr 17, 2012·10 cites·18 claims
- 1788US8765385B2Method of detection of neutralizing anti-actriib antibodiesKUMAR RAVINDRA·Filed 2011·Granted Jul 1, 2014·15 cites·8 claims
- 1888US8455428B2ALK1 receptor and ligand antagonist and uses thereofGRINBERG ASYA·Filed 2007·Granted Jun 4, 2013·8 cites·21 claims
- 1987US12384847B2Cancer therapy involving an anti-PD1 antibody and a multi-specific binding protein that binds NKG2D, CD16, and a tumor-associated antigenDRAGONFLY THERAPEUTICS INC·Filed 2019·Granted Aug 12, 2025·2 cites·20 claims
- 2087US12264200B2Antibody variable domains targeting the NKG2D receptorDRAGONFLY THERAPEUTICS INC·Filed 2023·Granted Apr 1, 2025·0 cites·18 claims
- 2187US10307455B2Activin type 2 receptor antibodiesACCELERON PHARMA INC·Filed 2017·Granted Jun 4, 2019·5 cites·14 claims
- 2287US10023621B2Follistatin-related fusion proteinsACCELERON PHARMA INC·Filed 2015·Granted Jul 17, 2018·5 cites·19 claims
- 2387US2024158468A1Tgf-beta superfamily type i and type ii receptor heteromultimers and uses thereofACCELERON PHARMA INC·Filed 2023·Application pending·0 cites
- 2486US10765626B2Methods for treatment of charcot-marie-tooth disease with follistatin polypeptidesACCELERON PHARMA INC·Filed 2018·Granted Sep 8, 2020·2 cites·27 claims
- 2586US10316076B2Transforming growth factor-beta receptor type II fusion polypeptidesACCELERON PHARMA INC·Filed 2017·Granted Jun 11, 2019·3 cites·19 claims
- 2686US10227392B2ALK7:ActRIIB heteromultimers and uses thereofACCELERON PHARMA INC·Filed 2016·Granted Mar 12, 2019·3 cites·29 claims
- 2786US10196434B2ALK4:ActRIIB heteromultimers and uses thereofACCELERON PHARMA INC·Filed 2016·Granted Feb 5, 2019·3 cites·31 claims
- 2886US9975934B2Follistatin-related fusion proteinsACCELERON PHARMA INC·Filed 2016·Granted May 22, 2018·3 cites·28 claims
- 2986US2025019444A1Antibody variable domains targeting the nkg2d receptorDRAGONFLY THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3085US12157771B2Proteins binding NKG2D, CD16 and CLEC12ADRAGONFLY THERAPEUTICS INC·Filed 2021·Granted Dec 3, 2024·1 cites·21 claims
- 3185US10010498B2Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteinsACCELERON PHARMA INC·Filed 2016·Granted Jul 3, 2018·2 cites·27 claims
- 3285US9624301B2Polynucleotides encoding an actriib antibodyACCELERON PHARMA INC·Filed 2016·Granted Apr 18, 2017·3 cites·4 claims
- 3385US2024374671A1Activin Type 2 Receptor Binding Proteins and Methods of Making ThemACCELERON PHARMA INC·Filed 2024·Application pending·0 cites
- 3484US11951156B2Methods for treating pulmonary hypertension with a ligand binding domain of a TGF-beta type II receptorBRIGHAM & WOMENS HOSPITAL INC·Filed 2020·Granted Apr 9, 2024·1 cites·17 claims
- 3584US2025368720A1Tgf-beta superfamily type i and type ii receptor heteromultimers and uses thereofACCELERON PHARMA INC·Filed 2025·Application pending·0 cites
- 3684US2024309098A1Alk7 antagonists and uses thereofACCELERON PHARM INC·Filed 2024·Application pending·0 cites
- 3783US11059894B2ALK7 binding proteins and uses thereofACCELERON PHARMA INC·Filed 2019·Granted Jul 13, 2021·1 cites·7 claims
- 3883US10682392B2Methods for treating pulmonary hypertension with a TGF-beta type II receptor-FC fusion proteinBRIGHAM & WOMENS HOSPITAL INC·Filed 2014·Granted Jun 16, 2020·4 cites·11 claims
- 3982US12258380B2ALK4:actriib heteromultimers and uses thereofACCELERON PHARMA INC·Filed 2022·Granted Mar 25, 2025·0 cites·20 claims
- 4082US9452197B2Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereofACCELERON PHARMA INC·Filed 2013·Granted Sep 27, 2016·2 cites·7 claims
- 4182US2023416379A1ALK7 Binding Proteins and Uses ThereofACCELERON PHARMA INC·Filed 2023·Application pending·0 cites
- 4281US12144860B2ALK1 receptor and ligand antagonists and uses thereofACCELERON PHARMA INC·Filed 2021·Granted Nov 19, 2024·0 cites·6 claims
- 4381US7833971B2Uses of cerberus, coco and derivatives thereofACCELERON PHARMA INC·Filed 2007·Granted Nov 16, 2010·3 cites·6 claims
- 4480US11440949B2TGF-beta superfamily type I and type II receptor heteromultimers and uses thereofACCELERON PHARMA INC·Filed 2017·Granted Sep 13, 2022·1 cites·15 claims
- 4580US10954279B2Methods and compositions for treatment of disorders with follistatin polypeptidesACCELERON PHARMA INC·Filed 2018·Granted Mar 23, 2021·1 cites·19 claims
- 4680US2025154261A1Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of useDRAGONFLY THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 4779US12421295B2TGF-beta superfamily type I and type II receptor heteromultimers and uses thereofACCELERON PHARMA INC·Filed 2022·Granted Sep 23, 2025·0 cites·11 claims
- 4879US12275791B2Multi-specific binding proteins that bind HER2, NKG2D, and CD16, and methods of useDRAGONFLY THERAPEUTICS INC·Filed 2019·Granted Apr 15, 2025·1 cites·6 claims
- 4979US12215157B2Multi-specific binding proteins that bind CD33, NKG2D, and CD16, and methods of useDRAGONFLY THERAPEUTICS INC·Filed 2019·Granted Feb 4, 2025·1 cites·40 claims
- 5079US11001614B2Method for treating a muscle-related disorder with follistatin-related fusion proteinsACCELERON PHARMA INC·Filed 2018·Granted May 11, 2021·1 cites·28 claims
Showing the top 50 of 131 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Asya Grinberg files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →